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Objective: To evaluate the long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.
Methods: 549 patients entered this 5-year, open-label extension study and received etanercept 25 mg
twice weekly. All patients showed inadequate responses to disease-modifying antirheumatic drugs before
entry into the double-blind studies. Safety assessments were carried out at regular intervals. Primary
efficacy end points were the numbers of painful and swollen joints; secondary variables included
American College of Rheumatology (ACR) response rate, Disease Activity Score and acute-phase
reactants. Efficacy was analysed using the last-observation-carried-forward approach.
Results: Of the 549 patients enrolled in the open-label trial, 467 (85%), 414 (75%) and 371 (68%)
completed 1, 2 and 3 years, respectively; 363 (66%) remained in the study at the time of this analysis. A
total exposure of 1498 patient-years, including the double-blind study, was accrued. In the open-label
trial, withdrawals for efficacy-related and safety-related reasons were 11% and 13%, respectively.
Frequent adverse events included upper respiratory infections, flu syndrome, rash and injection-site
reactions. Rates of serious infections and malignancies remained unchanged over the course of the study;
there were no reports of patients with central demyelinating disease or serious blood dyscrasias. After
3 years, ACR20, ACR50 and ACR70 response rates were 78%, 51% and 27%, respectively. The Disease
Activity Score score was reduced to 3.0 at 3 months and 2.6 at 3 years from 5.1. A sustained
improvement was found in Health Assessment Questionnaire scores throughout the 3-year time period.
Conclusion: After 3 years of treatment, etanercept showed sustained efficacy and a favourable safety
profile.
T
he introduction of biological antirheumatic treatments,
such as etanercept, in the late 1990s, represents a
qualitative advance in the practice of rheumatology. In
several well-controlled studies, etanercept versus placebo or
methotrexate markedly reduced disease activity and rate of
progression of joint damage, with limited toxicity.1–6 These
studies, of 24 months duration, contributed to the establish-
ment of the efficacy and safety profile of etanercept. To more
fully assess the long-term effects of treatment, studies of
longer etanercept treatment in patients with rheumatoid
arthritis are necessary.
Theoretical considerations in the long-term use of etaner-
cept include immunosuppression and its effect on the
development of infections and malignant tumours. To deal
with these concerns, long-term data are being accumulated
in this open-label extension study, which was conducted at
58 sites in 12 European countries. Incidence rates for
malignancy and infection may be compared with the back-
ground statistics available from large databases.
A summary of results based on 3-year data in this ongoing
study is presented in this report.
PATIENTS AND METHODS
Study design and patients
This is an ongoing, open-label, multicentre study on the long-
term effects of etanercept in patients with active rheumatoid
arthritis despite disease-modifying antirheumatic drug
(DMARD) treatment. The study started in 1998, after
completion of two randomised, double-blind, placebo-
controlled studies, in which patients received either placebo
or etanercept for up to 6 months (fig 1). In the open-label
study, which is expected to continue for up to 5 years, all
patients receive etanercept 25 mg twice weekly. The ethics
committee of each participating centre approved the study
protocol and the consent form. Before entering the open-label
study, each patient gave written informed consent.
To be included in the double-blind trials, patients had to
have failed at least one DMARD, have functional class I, II or
III of the American Rheumatism Association criteria for
rheumatoid arthritis, and meet the 1987 American College of
Rheumatology (ACR) criteria for rheumatoid arthritis. Active
rheumatoid arthritis is defined by the presence of >6 swollen
joints, >12 tender joints and one of the following criteria:
Westergren erythrocyte sedimentation rate (ESR) of
>28 mm/h, serum C reactive protein (CRP) concentration
of .20 mg/l, or morning stiffness for >45 min. Onset of
rheumatoid arthritis had to occur after age 16 years, and
disease duration (15 years.
Exclusion criteria for the double-blind studies included
relevant concurrent medical disease, including cancer,
Abbreviations: ACR, American College of Rheumatology; CRP, C
reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health
Assessment Questionnaire; LOCF, last observation carried forward;
NCI, National Cancer Institute; SAE, serious adverse event; SEER,
Surveillance, Epidemiology, and End Results; TEAE, treatment-emergent
adverse event; TNF, tumour necrosis factor
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uncompensated congestive heart failure, active infection, and
noticeable laboratory abnormalities. Other exclusion criteria
included use of any investigational drug (3 months before
screening for the double-blind studies, use of immunosup-
pressive agents, or previous administration of an anti-tumour
necrosis factor (TNF) agent other than etanercept. Women
with childbearing potential were asked to use contraception
during the study. The numbers of patients and etanercept
treatment regimens for the two double-blind studies are
shown in fig 1.
Drugs
During the open-label study, etanercept 25 mg was self-
administered subcutaneously twice weekly. Permitted con-
comitant drugs include non-steroidal anti-inflammatory
drugs, corticosteroids ((10 mg/day prednisolone or equiva-
lent), analgesics, and physical, herbal and homeopathic
treatments. No intra-articular corticosteroid injection was
permitted for the first 3 months. Thereafter, the total allowed
dose of corticosteroid injection did not exceed the equivalent
dose of 40 mg prednisone in any 3-month period. Treatment
with a DMARD or cytotoxic drug was prohibited.
Clinical evaluation
After completion of the double-blind studies, patients
entering the open-label study were evaluated clinically and
variables including swollen and tender joint counts (66/68
counts),7 pain Visual Analogue Scale (VAS), Health
Assessment Questionnaire (HAQ), and patient and physician
global assessments of disease activity were considered, at
baseline, week 2, week 4 and monthly thereafter. ESR and
CRP were assessed at baseline, week 2, week 4, and at 12-
week intervals, thereafter. Patients were evaluated by the
same assessor whenever feasible throughout the study.
Safety evaluations, including physical examination,
adverse experiences, vital signs, routine blood biochemistry
and haematology analysis, were carried out at week 2, week
4, and monthly thereafter, for the first year of the open-label
study and every 3 months thereafter, for the remainder of the
study.
An event was considered to be a treatment-emergent
adverse event (TEAE) if it occurred during the study or if the
severity or frequency of a pre-existing event increased during
the study. A serious adverse event (SAE) was any event that
resulted in death; was life threatening, required hospitalisa-
tion, or medical or surgical intervention; resulted in
persistent or marked disability, cancer; or was a congenital
defect. Infections were serious if they met the definition of an
SAE.
The incidence of malignancies was compared with the
National Cancer Institute’s (NCI) Surveillance,
Epidemiology, and End Results (SEER)8 database. The age-
specific and sex-specific incidence rates for cancer from the
SEER database were applied to the exposure in this study.
Statistical analyses
In this open-label study, the emphasis was on descriptive
statistics and the primary objectives were safety parameters.
The baseline used for safety parameters was the start of the
open-label study. Assessment of clinical efficacy of etanercept
was a secondary objective. The main efficacy end points were
numbers of painful and swollen joints. Efficacy parameters
analysed with the last observation carried forward (LOCF)
were based on patients who received at least one dose of
etanercept, the intent-to-treat population. Baseline values for
efficacy parameters were assessed before the start of
etanercept treatment—that is, before the double-blind trials
for patients who received etanercept—and before the open-
label study for patients who received placebo during the
double-blind trials.
The power of this study was estimated as the probability of
encountering >1 adverse event given a true underlying
incidence. With 549 patients, there is a 50% chance that an
adverse event with a 0.13% incidence would be observed, an
Study 1 Double blind, placebo controlled 
Duration 4 weeks, n = 70
ETN 10 mg QW
ETN 10 mg BIW
ETN 50 mg once in 2 weeks
ETN 50 mg BIW
Study 2 Double blind, placebo controlled
Duration up to 24 weeks, n = 559
ETN 10 mg QW
ETN 10 mg BIW
ETN 25 mg QW
ETN 25 mg BIW
Long term open label study
Duration 5 years 
Study 1 (n = 41), Study 2 (n = 508), Total (n = 549)
ETN 25 mg BIW
Figure 1 Flow chart of patients from the double-blind studies to the long-term open-label study. BIW, twice weekly; ETN, etanercept; QW, once
weekly.
Table 1 Patient baseline characteristics before treatment
Total enrolled 549
Mean age (years) 53
Women (%) 79
Patients on prior NSAIDs (%) 87
Patients on prior corticosteroids (%) 84
Mean no of prior DMARDs 3.3
No of tender joints 31.0
No of swollen joints 22.4
RF+ (%) 86.4
Mean RA duration (years) 7.4
DMARDs, disease-modifying antirheumatic drugs; NSAIDs, non-steroidal
anti-inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor.
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80% chance for an adverse event with a 0.30% incidence and
a 90% chance for one with a 0.44% incidence.
RESULTS
Patient characteristics
Table 1 summarises the characteristics of the patients before
treatment.
Exposure
In total 549 adult patients with rheumatoid arthritis received
etanercept 25 mg twice weekly. The minimum, maximum
and median exposure was 8 days, 3.92 and 3.34 years,
respectively. A total of 1396 patient-years have been accrued
in this open-label study.
Safety and tolerability
Throughout the study, the two most common reasons for
discontinuation from etanercept were adverse event and
unsatisfactory response (table 2). As on the cut-off date (31
August 2001), 363 patients continue to receive etanercept in
this ongoing trial.
We found no predominant adverse events leading to
discontinuation. The most common adverse events leading
to discontinuation were pruritus (n = 4), and abscess,
injection-site reaction, rash, sepsis, pneumonia, myocardial
infarction and pyogenic arthritis (n = 3 for each). The most
frequently reported TEAEs included upper respiratory infec-
tion, accidental injury, injection-site reaction and flu syn-
drome (table 3). We found no cases of demyelinating disease
of the central nervous system.
NCI grades (3 and 4) were used to identify patients with test
results of potential clinical importance. The most common
grade 3 and 4 laboratory abnormalities were increased alanine
aminotransferase (n = 12), low lymphocytes (n = 10) and low
albumin (n = 9). One patient had low platelet values (lowest
value = 356109/l) for three consecutive visits, but continued in
the study. Another patient had increased alanine aminotrans-
ferase for two consecutive visits. This patient was withdrawn
from the study because of a protocol violation, non-compliance
with study drugs. The remaining patients had transient grade 3
or 4 laboratory abnormalities. No persistent clinically relevant
laboratory abnormalities were found. Five patients (0.9%)
discontinued because of a laboratory abnormality that was not
classified as grade 3 or 4.
Serious infections
Rates of serious infections requiring hospitalisation or
requiring parenteral antibiotics remained unchanged over
the extended course of the study (table 4). The most
frequently reported serious infections were pneumonia,
upper respiratory infection, abscess, bronchitis, gastroenter-
itis, septic arthritis, sepsis, peritonitis and wound infection.
Of the 10 patients who died during or after discontinuation
from the study, 7 had infection as a contributory factor to
their deaths (table 5).
Of the 14 patients with a history of tuberculosis, none
experienced tuberculosis reactivation. One case of suspected
tuberculosis was reported in a patient in Spain with a history
of occupational pneumoconiosis (Caplan’s syndrome); this
patient had a positive tuberculin test without evidence of
mycobacterium.
Malignancies
Among the malignancies reported, no clustering around any
specific type of cancer was observed. The most commonly
reported tumour types were breast (n = 3) and lung (n = 2)
carcinomas. We found one report of lymphoma in a 59-year-
old patient with disease duration of 4.5 years and 323 days of
etanercept treatment. The patient was diagnosed with
Hodgkin’s lymphoma 8 months after discontinuing etaner-
cept treatment. Because malignancies develop over a long
time, the exposure data captured in table 6 included those of
the patients treated with etanercept in the double-blind
studies. The rates per patient-year remained stable through-
out the study. Compared with the SEER database, the
number of cases observed is lower (n = 11) than the number
of cases expected (n = 13), on the basis of etanercept
Table 2 Percentage (number) of patients who withdrew (primary reasons)
Reason for discontinuation Year 1 Year 2 Year 3 .3 years* Total
Any reason 15 (82) 10 (53) 8 (43) 1 (8) 34 (186)
Adverse events 5 (30) 4 (20) 3 (19) ,1 (4) 13 (73)
Unsatisfactory response 5 (29) 2 (11) 3 (16) ,1 (2) 11 (58)
Other non-medical event 1 (7) 3 (14) ,1 (1) ,1 (1) 4 (23)
Patient request 1 (6) 1 (6) ,1 (3) ,1 (1) 3 (16)
Protocol violation 2 (9) ,1 (2) ,1 (2) 0 (0) 2 (13)
Failed to return ,1 (1) 0 (0) ,1 (2) 0 (0) ,1 (3)
*Till the cut-off date (31 August 2001).
Table 3 Most frequently reported treatment-emergent
adverse events
Adverse event % of patients Events per patient-year*
Upper respiratory infection 38 0.34
Accidental injury 26 0.14
Injection-site reaction 26 0.43
Flu syndrome 21 0.11
Infection 19 0.10
Rash 17 0.09
Abdominal pain 16 0.09
Pharyngitis 15 0.08





Cough increased 13 0.07
Arthralgia 11 0.06
Hypertension 11 0.05
Urinary tract infection 11 0.07
Injection-site haemorrhages 10 0.35
*Open-label exposure.











Patient-years 501 446 448 1396
No of events 37 26 26 89
Infections per 100
patient-years
7.4 5.8 5.8 6.4
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exposure. Because the SEER database8 does not include non-
melanoma skin cancers, the two reports of basocellular skin
cancers were excluded from the comparison.
Efficacy
The percentage of patients meeting ACR20 criteria remained
relatively stable throughout the trial, and was at 77.8% at
month 36. Although not significant, the percentage of
patients meeting ACR50 increased with time on etanercept,
from 39.5% at month 3 to 50.6% at month 36. Similarly, the
ACR70 rate was 18.6% at month 3 and 27.0% at month 36
(fig 2). The mean baseline Disease Activity Score score of 5.1
decreased to 3.0 at month 3 and continued to decrease
thereafter (fig 3).
After 3 months of treatment, a substantial reduction in the
numbers of painful and swollen joints was achieved, 11.6
(63%) and 8.0 (65%), respectively. At 3 years, the numbers
were reduced to 8.9 (71%) and 6.2 (72%), respectively (fig 4).
The mean baseline CRP and ESR concentrations were
43.4 mg/l and 44.3 mm/h, respectively. At month 3, they
decreased to 17.5 mg/l and 26.2 mm/h, respectively, and at
month 36, to 12.1 mg/l and 24.8 mm/h, respectively (fig 5).
The baseline median HAQ score of 1.8 decreased to 1.1 at
3 months and was maintained thereafter; at month 36, the
median HAQ score was 1.1, representing a 39% improvement
from baseline (fig 3). The mean physician and patient global
assessments of 6.6 and 6.7, respectively, at baseline decreased
to 2.9 and 3.4, respectively, at month 3, with a small
additional improvement by month 36. Patient pain scores
improved from baseline by 50% at month 3 and by 49.2% at
month 36.




treatment Clinical profile at the time of death
32 Cardiorespiratory failure after recovery from peritonitis
and sepsis*
39 Disseminated carcinoma, sepsis*
53 Agranulocytosis (due to thiamazole), sepsis with
multiorgan failure*
221 Renal failure, cholecystitis, cholelithiasis*
716 Alcoholic hepatitis, pneumonia*
950 Sudden death, pneumonia*
1007 Car accident
1131 Acute heart failure
1149 Pulmonary embolism
1154 Cardiac arrest (chronic cardiomyopathy, possibly
pulmonary embolism, bacteraemia without clinical
symptoms of sepsis)*
*Associated with infection.











Patient-years* 516 455 527 1498




0.6 1.1 0.6 0.7
*Includes double-blind and open-label exposure data for those patients
who entered the extension trial.
Expected cases: 13 based on the National Cancer Institute Surveillance,


















Figure 2 Percentage of patients with American College of
Rheumatology (ACR)20, ACR50 and ACR70 response rates by study
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Months
Figure 3 Mean Disease Activity Score (DAS) and median Health

























Figure 4 Percentage change from baseline in the numbers of painful
and swollen joints by study month. *Baseline of previous double-blind
studies.
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DISCUSSION
This multicentre, open-label study confirmed that etanercept
monotherapy provides a sustained favourable efficacy and
safety profile. Retention rates were similar9 or higher10–13 than
those seen in long-term studies of etanercept and other
rheumatoid arthritis treatments. Over the 3 years, patients
showed no increase in TEAEs or SAEs, and there were no
reports of tuberculosis recurrence. The incidence of malig-
nancy was similar to that of the general population.
One limitation of this multicentre study is its open-label
design—that is, subjects and investigators are not blinded—
which could introduce bias. However, it would be inap-
propriate to consider a placebo-controlled study to evaluate
the long-term safety and efficacy of a treatment for
rheumatoid arthritis. Open-label studies with careful mon-
itoring and with the option of comparing results between
different time periods thus represent one important possibi-
lity of obtaining results that are of relevance to the clinical
practice.
In our study, 66% of patients were receiving etanercept
after 3 years. This retention rate is similar to the 63%
observed in a similar long-term study of North American
patients with rheumatoid arthritis.9 Adherence rates for
DMARD treatments are available only in published long-
term observational studies. In a 14-year prospective observa-
tional study of 671 patients with rheumatoid arthritis
attending an outpatient clinic,12 the approximate percentage
of patients remaining on treatment was 55% for methotrex-
ate, 40% for hydroxychloroquine, 39% for penicillamine, 39%
for gold injection and 35% for auranofin at 3 years.12
Regardless of study design, patients receiving inadequate or
unsatisfactory treatment would have a similar desire to
discontinue. Therefore, despite the differences in the studies
discussed here, the longer retention rates observed in our
open-label trial suggest that etanercept may be well tolerated
or more efficacious than most DMARDs.
In previously reported double-blind placebo-controlled
studies, the rate of infections with etanercept was not
markedly different from that with placebo.2 3 6 Adverse
events, including incidence of infection reported in this
open-label study, were comparable with those in the placebo
arm of the preceding double-blind study14 even after 3 years
of continuous drug exposure. This safety profile is reassuring,
because it has been assumed that long-term inhibition of
TNF would increase the risk of infection.15–17 However, the
data need to be interpreted with some caution, because this
long-term extension study included patients from two
randomised double-blind trials with strict inclusion and
exclusion criteria, which may differ from many clinical
practice populations in terms of comorbidities and drugs.
The association between tuberculosis and other intracel-
lular infections with various anti-TNF treatments is another
potential area of concern.18 Although patients with a history
of tuberculosis were not excluded from this study, none of
the 14 patients with a documented history of tuberculosis
had any recurrence or exacerbation of infection during the
trial. Tuberculosis was suspected in one patient from Spain
who received etanercept treatment for more than 3 years.
Another long-term potential consequence of TNF inhibi-
tion is an increased risk of malignancy secondary to the
possible role of TNF in tumorigenesis.19 In this long-term
study, the number of malignancies per patient-year, includ-
ing skin cancers, was reported to be 0.009. Although study
designs differed, rates of malignancies were similar to those
obtained from a long-term follow-up of 521 patients with
rheumatoid arthritis at the Mayo Clinic (Rochester,
Minnesota, USA) (0.018)20 and a controlled retrospective
cohort study of 623 patients with rheumatoid arthritis in The
Netherlands (0.012).21 Furthermore, in a register-based study
in Sweden on patients subject to treatment with TNF-
blocking agents in clinical practice, the standardised inci-
dence ratio (observed/expected numbers of cancers) was 0.9
(95% CI 0.7 to 1.2).22
The number of observed cases (n = 11) of malignancy is
fewer than that expected (n = 13) based on the age-matched
and sex-matched general population from the NCI SEER8
database, a database of cancers (not including non-mela-
noma skin cancers) that have been reported in North
America. The SEER database was used to provide an
approximation of the rate of malignancies in the general
population worldwide. Although not specific for Europe, this
database provides approximate rates of malignancy in the
general population. The incidence of malignancy was
relatively constant in each of the 3 years of treatment, with
no unusual clustering of any particular cancer. The one
reported case of lymphoma had a questionable relationship to
etanercept: the patient had received almost 11 months of
etanercept and developed Hodgkin’s lymphoma 8 months
after discontinuation. Overall, it seems that the malignancies
among this patient population are representative of a chronic
rheumatoid arthritis population.
Although the designs of the studies listed in table 7 were
different, mortality was consistent. The rate of seven
infection-related deaths per 1498 patient-years is comparable
with infection-related mortality in patients with rheumatoid
arthritis from published sources and a large US registry
(table 7).21 23–25
The extent to which the infections were associated with the
fatal outcome is not clear because most patients had other
comorbid conditions. Studies have shown that patients with
rheumatoid arthritis have higher mortality than the general
population.26 Gabriel et al27 reported that the risk of mortality
is approximately 38% greater in patients with rheumatoid
arthritis than in the general population. The risk was
dramatically higher at 55% in women with rheumatoid
arthritis than in the general population.27 Wolfe et al25
reported 4–13 times higher infection-related mortality for
patients with rheumatoid arthritis than for the general
population. For pneumonia, the mortality was 3–6 times
higher for patients with rheumatoid arthritis.25
Another concern in connection with anti-TNF treatment is
central demyelination. Although reports have described how
TNF inhibitors could worsen demyelinating conditions,28
there were no reports of demyelinating disease of the central
nervous system (eg, multiple sclerosis or optic neuritis) in
this long-term study. However, more long-term etanercept
exposure is required before a full assessment can be made.
The overall treatment response from any of the efficacy
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Figure 5 Median C reactive protein (CRP) and median erythrocyte
sedimentation rate (ESR) by study month. *Baseline of previous double-
blind studies. ULN, upper limit of normal.
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and maintained throughout the 3-year period. These results
are in agreement with a North American long-term open-
label study, which showed that the efficacy of etanercept is
sustained and well tolerated.10 Both studies enrolled similar
DMARD-refractory patients, who were not allowed to receive
other antirheumatic drugs during the trial. Consequently, the
results achieved in this study do not reflect the potential
additive effects of combination therapy.
Improvement in the signs and symptoms of rheumatoid
arthritis occurred early and were sustained over the 3-year
period. An ACR20 response rate >75% was achieved and
maintained from 3 to 36 months. This was similar to US
long-term data, in which 73% and 76% of patients treated
with etanercept achieved ACR20 response rate at 30 months10
and ,48 months.29 ACR50 and ACR70 response rates of
39.5% and 18.6%, respectively, seen 3 months after the start
of the open-label extension, tended to increase over the
36 months. The ACR50 results are consistent with previously
reported response rates in a double-blind, controlled trial.5
ACR70 response rate at 3 months is higher than that
observed after 3 months in other double-blind trials. One
possible explanation is that patients entering the open-label
trial were not etanercept-naive; they had received 1–
6 months of treatment during the double-blind trial.
Another potential factor is the open-label design; patients
have a more positive response when they know they are
receiving active drugs.
One of the challenges encountered when designing a long-
term study is accounting for missing data points or
discontinuations before the end of the study. We chose to
use the LOCF to capture the early responders who discon-
tinued for reasons other than lack of efficacy. An analysis
including only the patients completing 3 years could intro-
duce bias because these patients were more likely to be
treatment responders. In our study, ACR response rates
derived using a completers analysis were higher than the
rates derived using an LOCF analysis; percentages of ACR20,
ACR50 and ACR70 responders were 85.9%, 59.1% and 31.8%,
respectively, at 3 years.
Similar sustained responses were seen with the quality-of-
life measures on disability functions; the mean percentage
change from baseline for the HAQ score was improved by
40.7% at 3 months and maintained for 3 years. These results
are clinically relevant because patients with rheumatoid
arthritis experience varying degrees of physical impairment,
fatigue, reactive depression and weight loss.30
In conclusion, etanercept shows a favourable safety and
efficacy profile for .3 years of treatment, and continues to
provide significant clinical benefit in the patient population
evaluated in this study. Etanercept represents a long-term
treatment option in clinical practice.
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